Efficacy and Safety of Recombinant Human Growth Hormone in the Treatment of Growth Hormone Deficiency: A Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Trial

• Recombinant human growth hormone (rhGH) significantly improves height SDS and growth velocity in children with growth hormone deficiency. • A higher dose of rhGH (0.2 IU/kg/day) results in greater growth outcomes compared to a lower dose (0.1 IU/kg/day). • rhGH treatment is generally safe, with mild and transient adverse events such as injection site reactions and elevated liver enzymes. • The study supports the use of rhGH as an effective therapy for pediatric GHD, with dose optimization important for maximizing growth benefits.